Current Cardiovascular Risk Reports

, Volume 1, Issue 4, pp 303–309

Low-molecular-weight heparin use in acute coronary syndromes and percutaneous coronary interventions: An update

Authors

  • Jeffrey J. Link
  • John J. Warner
    • University of Texas Southwestern Medical Center
Article

DOI: 10.1007/s12170-007-0049-x

Cite this article as:
Link, J.J., Warner, J.J. & de Lemos, J.A. Curr Cardio Risk Rep (2007) 1: 303. doi:10.1007/s12170-007-0049-x

Abstract

Based on important studies published in the past year, the role of low-molecular-weight heparin in acute coronary syndromes and percutaneous coronary interventions has continued to evolve. For patients with non-ST-elevation acute coronary syndromes, several alternatives to enoxaparin have been introduced, including fondaparinux and bivalirudin. In patients with ST-elevation myocardial infarction, recent studies have demonstrated a clear mortality benefit from adjunctive antithrombin therapy and the superiority of a prolonged course of enoxaparin over a standard duration of unfractionated heparin. Furthermore, recent data have demonstrated the safety of enoxaparin as an alternative to unfractionated heparin among patients undergoing percutaneous coronary interventions.

Copyright information

© Current Medicine Group LLC 2007